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Background: Post-traumatic depression (PTD) is a common condition after traumatic brain injury 
(TBI), which is believed to be potentiated by systemic inflammation. The objective of this study 
was to study the role of early chronic (1-3 months post-TBI) systemic neuroinflammation on 12 
months PTD following moderate-to-severe TBI and build prediction models.  
Methods: Data from participants (n=149) recruited from inpatient rehabilitation centers at the 
University of Pittsburgh Medical Center (UPMC) was used. Distributions 33 different 
neuroinflammatory markers, derived from blood samples collected 1-3 months post-injury, were 
graphed. Descriptive statistics for selected covariates (age, sex, injury severity, 1-6 months 
antidepressant use history, premorbid depression) were summarized using mean, median, 
interquartile range (IQR), standard deviations (SD), and percentages (%). Simple logistic 
regressions were used to identify several biomarkers associated with PTD (p-value <0.10). 
Principal components analysis (PCA) and ridge regression were then employed to create an overall 
inflammatory load score (ILS). PTD prediction model performance was compared using a logistic 
regression and a random forest modeling and their variations (up-sampling) using both internal 
and external validations. 
Results: 1-3 months MIP-1α, RANTES, ITAC, MIP-3α, IL-1b, TNFα, sIL-6R, IL-21, GM-CSF, 
MIP-1b, IL-7, IL-10, and Fractalkine were associated (p-value < 0.10) with 12 months PTD in the 
univariate logistic regressions. The ridge regression-based ILS outperformed the first three PCA-
based ILS [area under the curve, AUC=84.52% (ridge) vs. 83.62% (3-PCA) and 81.62% (1-PCA)]. 
 v 
An internal validation approach using 100 bootstrapped datasets identified random forest model 
with up-sampling procedure as the best performing model (92.4% average accuracy, 69.9% 
average sensitivity, and 96.2% average specificity). PTD significantly mediated the ILS-functional 
outcomes relationships.     
Conclusion: Early chronic systemic inflammation specific to different areas of immune function 
can help predict PTD with considerable accuracy. A random forest model with an up-sampling 
procedure performed better than logistic regression in all prediction metrics using a robust internal 
(bootstrapping) validation.  
Public health significance: Depression is treatable, and biomarkers associated with depression 
have utility as a screening tool for PTD prevention and early treatment, minimizing negative 
consequences like suicidality. It may have additional benefits for daily functioning, including 
cognition, behavior, and community reintegration.      
Keywords:  depression, neuroinflammation, traumatic brain injury. 
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More than 2.8 million individuals are diagnosed each year with traumatic brain injury 
(TBI) (Taylor et al., 2017). The lifetime costs of TBI in USA is estimated at $60 billion annually 
(Langlois et al., 2006). The pathophysiology of TBI includes the primary trauma and secondary 
neuro-metabolic crisis potentiated by inflammation, excitotoxicity, ischemia, and edema. 
Depression is one common secondary condition after TBI (Jorge et al., 2004). The economic 
burden of depression is estimated at $210 billion annually in the general population (Greenberg et 
al., 2015). Approximately one-third of general people diagnosed with depression fail standard 
treatment (The Council on Scientific Affairs, American Medical Association et al., 1999). Because 
depression is both prevalent and treatable, prevention and early detection are of great importance 
for clinicians. Previous research showed patients with TBI are roughly 7.9 times more likely to 
develop depression compared to the general population (Juengst et al., 2015). Correctly predicting 
depression status among individuals with TBI may help reduce risky behaviors like suicidal 
endorsement and attempts. The identification of individualized biomarkers associated with TBI 
and depression may help predict risk of depression after TBI.  
Neuroinflammation and post-traumatic depression 
Neuroinflammation is known as a secondary injury mechanism following TBI and a major 
contributor to chronic outcomes (Donat et al., 2017; Kim et al., 2015). The role of 




2012; Xu et al., 2017). Importantly, neuroendocrine-immune cross-talk, governed by the 
autonomic nervous system and the hypothalamic-pituitary-adrenal (HPA) and hypothalamic-
pituitary-gonadal (HPG) axes coordinate key signaling of cellular immunity and chemokine 
signaling in the periphery that impacts neuroinflammation (A. K. Wagner & Kumar, 2019).  
Systemic inflammatory mediators have been shown in multiple studies to both influence and 
reflect neuroinflammatory pathology associated with major depressive disorder (MDD) (R. 
Dantzer, 2008; D’Mello & Swain, 2016; Moriarity et al., 2020) and secondary depressive 
syndromes including that recently observed among those with the novel coronavirus (COVID-19) 
(Steardo & Verkhratsky, 2020).  Systemic inflammation has been associated with anti-depressant 
non-responsiveness (Bombardier, 2010). It is also known to be associated with post-traumatic 
stress disorder (PTSD) (von Känel et al., 2010), which is commonly known to co-occur with 
depression (Gros et al., 2012). The role of acute inflammation on post-traumatic depression (PTD) 
was studied in the TBI space and sVCAM-1, sICAM-1, and sFAS, which are generally related to 
death and damage of cells and platelets causing inflammation, were found to be associated with 6-
month PTD (Juengst et al., 2015). The role of chronic inflammation on depression has long been 
identified (Michael Maes, 1995; Michael Maes et al., 2012), but early chronic inflammation in 
relation to PTD has remained under-studied in the TBI space, which if associated with PTD, can 
be very informative for clinicians to detect and treat depression early.  
The Department of Physical Medicine and Rehabilitation of the University of Pittsburgh 
collects data, including blood samples on TBI patients from the level 1 inpatient rehabilitation 
center at the University of Pittsburgh Medical Center (UPMC) facilities including Presbyterian 




inflammatory responses in serum samples, believed to be related to different patient outcomes post 
injury, using a Luminex® bead array assay. These multiplex assays used microsphere technology 
where assay beads were tagged with various fluorescent-labeled markers. The binding for each 
protein onto the multiplex bead was analyzed with a fluorescence detection laser optic system. The 
Human High Sensitivity T cell Magnetic Bead Panel included interleukin (IL)-10, IL-12p70, IL-
13, IL17A, IL-1β, IL-2, IL-21, IL-4, IL-23, IL-5, IL-6, IL-7, IL-8, Macrophage Inflammatory 
Protein (MIP)-1α, MIP-1β, Tumor Necrosis Factor (TNF)-α, Fractalkine, Granulocyte 
Macrophage Colony Stimulating Factor (GM-CSF), Interferon-inducible T-cell alpha 
chemoattractant (ITAC) and Interferon (IFN)-γ. The Human Neurodegenerative Disease Magnetic 
Bead included soluble Intracellular Adhesion Molecule (sICAM)-1, Regulated upon Activation, 
Normal T-cell Expressed and Secreted (RANTES), Neural Cell Adhesion Molecule (NCAM) and 
soluble Vascular Adhesion Molecule (sVCAM)-1. The Human Soluble Cytokine Receptor 
Magnetic Bead Panel included soluble (s)CD30, soluble glycoprotein (sgp)130, soluble IL-1 
receptor (sIL-1R)-I, sIL-1RII, sIL-2α, sIL-4R, sIL-6R, sTNFRI, and sTNFRII.  Assay specifics for 
these data have been described in detail and published elsewhere (Vijapur et al., 2020). 
Often individual interpretations of these biomarkers are not of direct importance because 
biologically they work together as a complex signaling network to influence PTD. An overall 
composite score representing a patient’s inflammatory profile or inflammation burden, created by 
the biomarkers that influence PTD, could be more relevant in understanding the biodiversity of 
the immune system in its relationship to PTD. Such an overall composite score can also be created 
as a linear combination of discriminant inflammatory biomarkers and be called an inflammatory 




an inflammatory load score for PTD prediction. The main articles on such an score formulation 
for other outcomes were mostly based on an unweighted approach (R. G. Kumar et al., 2015; Raj 
G. Kumar et al., 2015; Santarsieri et al., 2015). Since inflammatory biomarker cascades are usually 
correlated, stable weights corresponding to the biomarkers in the linear combination can be 
obtained using methods such as principal component analysis (PCA) or ridge regression. Weights 
obtained by PCA do not depend on the outcome of interest, while weights obtained by ridge 
regression are predicated on the inflammatory relationship to outcome.  
Role of other covariates on post-traumatic depression 
Patient characteristics such as age, sex, and injury severity can influence inflammatory 
response and hence may have an impact on PTD. Individuals with preinjury psychological disorder 
or diagnosis of depression can also be related to post-injury depressive symptoms (Alway et al., 
2016; Bombardier et al., 2016; Rogers & Read, 2007). Information on medications, especially 
antidepressants that individuals were taking prior to injury can help inform and predict later 
depression (Price et al., 2011), although antidepressants may be less effective among patients with 
TBI (Neurobehavioral Guidelines Working Group et al., 2006). Lesions identified on computed 
tomography (CT) scan data during acute hospitalization may also reflect differences in long-term 
health outcomes, such as depression (Hamani et al., 2011; Hudak et al., 2011; Koolschijn et al., 
2009; Maller et al., 2010; Mayberg, 2003; Mettenburg et al., 2012; Sheline et al., 2003). 
Concurrent employment and substance abuse can also be related to depression (Awan, DiSanto, 
Juengst, Kumar, Bertisch, Niemeier, Fann, Kesinger, et al., 2020). For predictive models the 
concurrent variables are not relevant, but our previous research shows preinjury employment and 




Juengst, Kumar, Bertisch, Niemeier, Fann, Sperry, et al., 2020), so these variables can be brought 
in to see how well they help predict 12 months depression.   
Self-reported MDD through Patient Health Questionnaire-9 (PHQ-9) is often categorized 
as a binary (depressed/non-depressed) outcome (Fann, Berry, et al., 2009). Of note, PHQ-9 is a 
validated self-administered battery for screening symptom endorsement and symptom severity 
associated with MDD; this instrument scores each of the 9 Diagnostic and Statistical Manual-IV 
(DSM-IV) criteria for MDD as “0” (not at all) to “3” (nearly every day). Logistic regression is an 
old and widely used method for binary classification (Cox & Snell, 1969). There are more recent 
tree-based algorithms such as random forest that can also perform binary classification. Logistic 
regression describes the relationship between one dependent binary variable and one or more 
nominal, ordinal, interval or ratio-level independent variables. Random forests, also known as 
random decision forests, are a popular ensemble method that can be used to build predictive models 
for both classification and regression problems. Ensemble methods use multiple learning models 
to gain better predictive results.  For the random forest, the model creates an entire collection of 
random uncorrelated decision trees to arrive at the best possible prediction. The ideas of `bagging' 
(selecting subsets of features and growing the full trees) and ensembles (combination of decision 
trees to increase the classification accuracy) were popularized by an extension of the very first 
algorithm of random forest (Ho, 1995) and the algorithm developed by Leo Breiman (Breiman, 
2001).  
There have been several studies that have compared the predictive performance of a logistic 
regression and a random forest with different datasets. One such study compared the prediction 




show superior prediction accuracy of one approach over another under different conditions. For 
example, logistic regression can work equally well when signal-to-noise is low, and the sample 
size is comparatively small, but random forest will be superior with more data on the same 
problem. Logistic regression is still used even when less predictive because it is more interpretable 
and faster. However, model performance should be evaluated through some kind of cross-
validation before deciding which approach has better predictive accuracy. Tuning any parameter 
for improved model performance should be based on the out-of-sample model performance 
measures (average over the hold-out folds in a cross-validation, for example) and order of sampling 
should be maintained during cross-validation while comparing multiple models.   
Objectives of the study 
The primary objective of this study was to investigate the influence of early measures of 
chronic systemic inflammation on 12 months depression after moderate-to-severe TBI adjusting 
for premorbid depression, injury severity, demographic characteristics, and other features specified 
above. The secondary objective was to compare PCA-based and ridge regression-based ILS 
calculations. The third objective was to compare the predictive performance of a logistic regression 
and a random forest model in predicting PTD. This study can support early detection and proactive 
treatment of “at risk” individuals in order to prevent or reduce the functional devastation associated 





In this section, I discuss the data source and variables in subsection 2.1, the description of 
the statistical methodology used in subsection 2.2, and statistical analyses in the order they were 
performed in subsection 2.3. I used PCA to derive the PCA-based ILS, logistic regression with 
ridge penalty (including only selected biomarkers) to derive the ridge-based ILS, and then 
compared PCA-based and ridge-based ILS to find which one performed better in a logistic 
regression with other covariates. Finally, I selected the ridge-based ILS (based on area under the 
curve (AUC)) for further analysis and compared the prediction performance of logistic regression 
and random forest. Logistic regression was used twice: first, to derive the ridge-based ILS (using 
only the biomarkers) and then while comparing the predictive models (using ILS and all other 
covariates). 
2.1 Data 
2.1.1 Data source and participants 
Data from a prospective cohort study of individuals (N=149) with moderate-to-severe TBI, 
recruited from the inpatient rehabilitation centers through Mercy (MER) facilities at the University 
of Pittsburgh Medical Center (UPMC), were collected and analyzed. Moderate-to-severe TBI 




head CT scan, loss of consciousness >30 minutes, and/or post-traumatic amnesia >24 hours 
(Carlson et al., 2009). Patients were followed up to 15 months post injury in accordance with site-
specific institutional review board approved protocols and provided informed consent. In order to 
be included in the analysis, participants must have had an indicator of post-traumatic depression 
(PTD) at 12 months, as defined below.  
2.1.2 Outcome 
The main outcome of interest was post-traumatic depression (PTD) at 12 months following 
moderate-to-severe TBI. PTD status was calculated by using the Patient Health Questionnaire-9 
(PHQ-9), which consists of items where subjects are asked if they have been bothered by the 
following problems in the past two weeks: 1) little pleasure or interest in doing things (anhedonia), 
2) feeling down, depressed, or hopeless (depressed mood), 3) sleeping too little or too much, 4) 
feeling tired or having little energy, 5) poor appetite or overeating, 6) feelings of worthlessness or 
guilt, 7) concentration problems, 8) psychomotor retardation or agitation, and 9) thoughts of 
suicide (“Thoughts that you would be better off dead or of hurting yourself in some way”). The 
PHQ-9 has demonstrated appropriate validity to be used as a screening tool for MDD. In 
accordance with Diagnostic and Statistical Manual-IV (DSM-IV) criteria for diagnosing MDD, 
participants were characterized as having PTD if they reported at least five symptoms, including 





We initially included 34 different inflammatory responses (pro- and anti-inflammatory 
cytokines) that were measured using a Luminex® bead array assay: IL-2, IL-1b,  IL-4,  IL-5,  IL-
6, IL-7, IL-8, IL-10, IL-12p70, IL-13, IFN-gamma, GM-CSF, TNF𝛼, ITAC, Fractalkine, MIP-3a,  
IL-17A, IL-21, IL-23, MIP-1a, MIP-1b, sTNFRI, sCD30, sgp130, sIL-1RI, sIL-1RII, sIL-2Ra, 
sIL-4R, sIL-6R, sTNFRII, sICAM-1, RANTES, NCAM, sVCAM-1. We excluded sIL-1RI as it 
was poorly assayed and was highly missing (data unavailable at all time points for about 70% of 
individuals in the study).We also included characteristics such as age, sex, injury severity, pre-
existing psychological disorder (Yes/No), premorbid employment (Yes/No), premorbid substance 
abuse (Yes/No), and use of antidepressant during first 6 months post-injury (Ever/Never) as 
covariates. The list of antidepressants used to extract the information on antidepressant use status 
is provided below in Table 1. 
Table 1: List of antidepressants used to identify 1-6 months antidepressant use status 
Tricyclics: Anafranil (clomipramine), Asendin (amoxapine), Elavil (amitriptyline), Norpramin 
(desipramine), Pamelor (nortriptyline), Sinequan (doxepin), Surmontil (trimipramine), 
Tofranil (imipramine), Vivactil (protiptyline) 
Selective serotonin reuptake inhibitors (SSRIs): Celexa (citalopram), Lexapro 
(escitalopram), Luvox (fluvoxamine), Paxil (paroxetine), Prozac (fluoxetine), Zoloft 
(sertraline) 




Others: Desyrel (trazadone) 
 
The Glasgow coma scale (GCS) was used to measure the severity of the neurological 
injury. This tool rates a patient's level of injury on 4-6-item scales based on assessing eye opening, 
verbal, and motor response. GCS ranges from 3-15 and lower scores mean more severe 
neurological injury (The Glasgow Structured Approach to Assessment of the Glasgow Coma Scale, 
n.d.). Computed tomography (CT) scan data were available from individual medical records 
obtained at various time point during acute hospitalization on subdural hemorrhage (SDH), 
subarachnoid hemorrhage (SAH), extradural hematoma (EDH), intraventricular hemorrhage 
(IVH), intraparenchymal hemorrhage (IPH), intracerebral hematomas (ICerH), diffuse axonal 
injury (DAI), and contusion. Based on other CT subtypes, evidence of intracranial hemorrhage 
(ICH), and extra- and intra-axial lesions were also created. 
Aside from the inflammatory biomarkers and CT variables, we also considered other 
covariates to use as adjustments, regardless of their significance in bivariate analyses. For example, 
premorbid depression was associated with 12-months PTD status in one study (Ouellet et al., 
2018). Also, we assumed that first 6 months antidepressant use status post-TBI could also inform 
12-months PTD. Age and sex are well known risk factors to be adjusted for in most 
epidemiological studies. We adjusted for neurological injury severity, since differing levels of 
injury severity can result in different levels of recovery. We also included preinjury psychological 
disorder as a covariate, as PTD can develop directly or indirectly through pre-existing 





2.2 Statistical methods 
The statistical methods used in this dissertation are described below in the order they were 
used. 
2.2.1 Principal components analysis (PCA) 
Principal component analysis (PCA) is a popular dimension-reduction technique that 
explains the variance-covariance structure of a set of variables through a few linear 
combinations of these variables. We have used PCA to explain the variation in the correlated 
biomarkers using only the first few dimensions. If 𝑋1, 𝑋2, … , 𝑋𝑝 are p random variables with 
variance-covariance matrix Σ and correlation matrix 𝜌, which has eigenvalues 𝜆1 ≥  𝜆2 ≥
⋯ ≥  𝜆𝑝 ≥ 0, and corresponding eigenvectors 𝑒1 = [𝑒11, 𝑒12, … , 𝑒1𝑝], 𝑒2 =
[𝑒21, 𝑒22, … , 𝑒2𝑝] , … , 𝑒1 = [𝑒𝑝1, 𝑒𝑝2, … , 𝑒𝑝𝑝], then the linear combinations 
𝑌1 = 𝑒11𝑋1 + 𝑒12𝑋2 + ⋯ + 𝑒1𝑝𝑋𝑝 









are called the principal components, where 𝑉𝑎𝑟(𝑌𝑖) = 𝑒𝑖Σ𝑒𝑖
𝑇 = 𝜆𝑖 and 𝐶𝑜𝑣(𝑌𝑖, 𝑌𝑘) = 𝑒𝑖Σ𝑒𝑘
𝑇 
for 𝑖, 𝑘 = 1, 2, … , 𝑝. Hence, the variance explained by the first principal component (𝑌1) is 
the maximum and can often be taken to represent the index for variables 𝑋1, 𝑋2, … , 𝑋𝑝.  
2.2.2 Logistic regression 
For binary (Bernoulli) response variable 𝑌, where 𝑌 = 0, 1, such as in our case where the 
outcome is PTD (𝑌 = 1) or no PTD (𝑌 = 0), if 𝑃(𝑌 = 1) = 𝑝, then for covariates 




= 𝛽1𝑋1 + 𝛽2𝑋2 + ⋯ +  𝛽𝑘𝑋𝑘. 
This regression models the log odds of 𝑌 = 1 and the predicted probability is given by,  
 ?̂? =
𝑒?̂?1𝑋1+?̂?2𝑋2+⋯+ ?̂?𝑘𝑋𝑘  
1 + 𝑒?̂?1𝑋1+?̂?2𝑋2+⋯+ ?̂?𝑘𝑋𝑘  
. 
   
2.2.3 Logistic regression with ridge penalty 
Ridge penalty stabilizes the coefficients and their standard errors in the presence of 
correlated data. The biomarkers considered in this study are correlated because of their 
biological function. We used the ridge-based penalty to stabilize the β coefficients and 
used the predicted 𝑋β as the linear combination of the correlated biomarkers, where 𝑋 is 




with p predictors and a column of ones to accommodate the intercept, and β is the column 
vector of the regression coefficients, then the constrained maximization for penalty 
parameter  is given by the following (Duffy & Santner, 1989; Le Cessie & Van 
Houwelingen, 1992):  









The coefficients obtained by maximizing this equation are more stable when the predictors 
are correlated because adding some bias reduces the variance of the parameter estimates. 
The predicted log odds using these coefficients can be used as an outcome-dependent 
index of the correlated predictors. 
2.2.4 Random forest for binary classification 
Random forest is a process of combining many decision trees with bootstrapped data 
producing different leaf nodes. For binary classification problem (e.g. PTD/no PTD), it 
merges the classification of all decision trees and counts the maximum vote for 
classification. How nodes on a decision tree branch depends on the Gini index, which is 
given by, 









where 𝑝𝑖 represents the relative frequency of the class we are observing in the dataset 
and c represents the number of classes (c=2 in our case). This index ranges from 0 
(homogeneous) to 1 (heterogeneous) and is a measure of how each variable contributes to 
the homogeneity of the nodes and leaves in the resulting random forest. Each time a 
variable is used to split a node, the Gini coefficient for the leaf nodes are calculated and 
compared to that of the original node. The root of each split is chosen based on the variable 
split with the lowest Gini index. 
2.2.5 Up-sampling 
When data are imbalanced in terms of outcome cases and non-cases, the most used 
classification algorithms do not work well because the focus of these algorithms is minimizing the 
error rate rather than identifying positive cases correctly. While this effect can be minimized by 
moving along the threshold for classification, over-sampling the minority class can sometimes 
produce better sensitivity (Kuhn & Johnson, 2013; Ling & Li, 1998). The process involves 
resampling the minority class to increase the corresponding frequencies or weights by replication, 
without increasing information (Chen et al., 2004). Both logistic regression and random forest 
were performed using up-sampling of PTD cases and the predictive performance metrics were 
compared with the ones where the threshold was chosen based on fixing sensitivity (at 80%) using 




2.2.6 Diagnostic and prediction accuracy metrics 
To compare the diagnostic ability of different logistic regression models, as their 
discrimination threshold is varied, the receiver operating characteristic (ROC) curve is a 
widely used graphical tool. The concordance statistic (c-statistic) or area under the curve 
(AUC) is the probability that a classifier will rank a randomly chosen positive instance 
higher than a randomly chosen negative one (assuming 'positive' ranks higher than 
'negative'). AUC ranges between 0 and 1 and higher values mean greater discriminative 
capability. For a 2-class prediction problem, prediction accuracy measures are based on the 
confusion matrix, which can be defined as follows.  
Confusion Matrix Reference/True category 
Predicted category Event No Event 
Event A B 
No Event C D 
  
The accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive 





































𝑌𝑢𝑑𝑒𝑛′𝑠 𝐼𝑛𝑑𝑒𝑥 = 𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 + 𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 − 1. 
We have evaluated these metrics using an external validation with a 70-30 split of the 
original data into training and test sets. Because our sample size was small with complete 
data on all biomarkers and covariates, we also performed a ‘strong internal validation’  which 
is often recommended instead of a split or k-fold cross validation when the sample size is 
small (Harrell Jr & Slaughter, 2001). This validation process involves taking a bootstrap 
sample from the original data and using it as a training set. The model built on the training 
set is tested on the original sample. Hence the original sample now serves as a test set. The 
bootstrapping is repeated B times and the average of the performance metrics on the test set 




2.3 Statistical analysis 
2.3.1  Descriptive analysis  
Medians of monthly values of 1-3 months biomarkers were used to represent a measure of 
early chronic biomarkers. A median is not affected by outliers; hence this also took care of any 
possible outliers present in the biomarker data. We calculated the descriptive statistics of the 
covariates by PTD status using summary measures mean, median, interquartile range (IQR), and 
standard deviation (SD) for continuous variables, and percent (%) for categorical variables. The 
Wilcoxon rank-sum (Mann-Whitney) test, Chi-square test, and logistic regression were used to 
test for bivariate associations with PTD.   
2.3.2 Inflammatory load score (ILS) 
Since inflammatory responses are typically highly correlated to each other, it is often of 
interest to look at the burden of the inflammatory responses rather than the biomarkers 
individually. To do this, clinicians can create an ILS using inflammatory biomarkers to represent 
an individual’s inflammatory burden by weighting each inflammatory marker based on its 
importance. This composite score can provide an overall idea about a individual inflammatory 
burden, which could be more relevant to the clinicians in making treatment-related decisions. 
The first step of creating the ILS for our study was to assess which biomarkers were 




techniques require complete data on all biomarkers, therefore using a variable selection technique 
requiring complete data on all 33 biomarkers would significantly reduce the analytic sample size.  
Our biomarker data had high missingness due to random assay failures or research participant loss 
to follow up, and all biomarker values were not available for the study participants. Therefore, 
selecting only a subset of these 33 biomarkers would result in less missingness in the ILS creation 
procedures described below, maximizing our analytic sample size. The variables were 
standardized (mean-centered and scaled by the standard deviation) to show the change in odds 
ratio (OR) for one standard deviation change in the standardized biomarker to make the ORs 
comparable (Agresti, 2003).     
Two potential methods of creating this ILS are to use: 1) principal component analysis 
(PCA) or 2) ridge regression. In PCA, the components are the linear combinations of original 
biomarkers with different weights that represent the correlation of the biomarkers and the 
component scores.  Ridge regression introduces a small amount of bias to reduce the variance of 
the estimates and weight the biomarkers based on their association with the outcome. The predicted 
log odds from this ridge regression can be taken as a weighted inflammatory load score (wILS) 
that is equivalent to a weighted sum of the biomarker levels. Both methods deal with high 
dimensionality of the inflammatory markers. PCA is a dimension-reduction technique that 
produces principal components only based on the biomarkers that maximize the variation in the 
biomarker space. It does not weight the biomarkers based on any outcome associated with the 
biomarkers. Ridge regression is a modelling approach which uses information regarding the 




the predictive model, as the weights derived from the training set will be applied to the validation 
set, wherein the association betwen PTD and the candidate inflammatory biomarkers could differ.   
We created two versions of the ILS based on PCA and ridge regression. The composite 
score created by using a ridge regression model will be called a weighted ridge-based inflammatory 
load score and the composite score by using a PCA will be called a weighted PCA-based 
inflammatory load score.  We used ridge regression to create the ILS because 1) the biomarkers 
are usually correlated among themselves to some degree and 2) we weighted the biomarkers 
depending on their relationship to PTD, adjusting for other covariates and all other biomarkers. 
Ridge regression improves the feasibility of generating more reliable estimates (with reduced 
standard error) by adding a penalty term in the presence of multicollinearity (Hoerl & Kennard, 
1970). We performed a 5-fold cross validation (CV) 1000 times to choose the most stable ridge 
penalty parameter using the R package glmnet (Friedman et al., 2010). We multiplied these 
coefficients with the log scaled biomarkers to get a weighted ILS. For PCA, we used the base 
function princomp in R and multiplied the biomarker values with the loadings of the first 
component to get the PCA-based ILS.  
2.3.3 Predictive models: logistic regression and random forest 
We used the ILS along with age, sex, GCS, antidepressant use, preexisting psychological disorder 
and premorbid depression to find the association of the ILS with PTD. To compare the 




receiver operating characteristic (ROC) curve. From this we selected the ILS that had greater 
discriminatory power.  
  We also compared the predictive performance of logistic regression model to 
random forest for our problem. To assess model performance in the study, we performed an 
external validation by dividing the data into training and test sets with a 70-30 ratio and a ‘strong 
internal validation’ by taking 100 bootstrap samples. When comparing the predictive ability of the 
logistic regression and random forest, we used ROC, confusion matrix, sensitivity, specificity, 
accuracy, PPV, NPV, detection rate, and detection prevalence. We compared both models through 
a 5-fold cross-validation repeated 10 times. The logistic regression and random forest models and 
their corresponding accuracy measured were obtained using the caret package in R. All analyses 







3.1 Descriptive statistics 
The sample characteristics by PTD status are presented in Table 2. Among the study participants, 
76.5% were men and 23.5% were women with an average age of approximately 39 years. Among 
them, 18.1% had premorbid depression, 31.5% had pre-existing psychological disorder and 28.9% 
had record of antidepressant use in the first 6 months after their injury. The percentages of CT 
lesions are also recorded. The Fisher’s exact test showed that participants with premorbid 
depression had a higher prevalence of depression at 12 months (33.3%) compared to those who 
did not have premorbid depression (14.1%). None of the other variables were significantly 
different between PTD and no PTD status. 
Table 2: Descriptive statistics of the covariates by PTD status at 12 months (row percentages presented in the 









Age at injury    0.792
⁎ 
Mean (SD) 38.9 (17.6) 38.3 (15.2) 39.1 (18.3)  








Sex    0.126† 
Male 114 (76.5%) 20 (17.5%) 94 (82.5%)  
Female 35 (23.5%) 11 (31.4%) 24 (68.6%)  
GCS    0.847⁎ 
Mean (SD) 8.43 (3.48) 8.48 (3.35) 8.42 (3.53)  



















Missing 4 0 4  
Premorbid depression    0.045†† 
Present 27 (22.7%) 9 (33.3%) 18 (66.7%)  
Absent 92 (77.3%) 13 (14.1%) 79 (85.9%)  
Missing 30 9 21  
Pre-existing psychological disorder    0.550† 
Present 47 (32.6%) 12 (25.5%) 35 (74.5%)  
Absent 97 (67.4%) 19 (19.6%) 78 (80.4%)  
Missing 5 0 5  
Antidepressant use (first 6m)    0.236† 
Yes 43 (31.9%) 8 (18.6%) 35 (81.4%)  
No 92 (68.1%) 
19 
(20.65%) 
73 (79.35%)  
Missing 14 4 10  
CT SDH    0.465† 
Present 96 (69.6%) 23 (24.0%) 73 (76.0%)  
Absent 42 (30.4%) 7 (17.7%) 35 (83.3%)  
Missing 11 1 10  
CT SAH    0.523† 
Present 97 (70.3%) 23 (23.7%) 74 (76.3%)  
Absent 41 (29.7%) 7 (17.1%) 34 (82.9%)  
Missing 11 1 10  
CT EDH    0.784†† 
Present 22 (15.9%) 4 (18.2%) 18 (81.8%)  
Absent 116 (84.1%) 26 (22.4%) 90 (77.6%)  
Missing 11 1 10  
CT IVH    0.288† 
Present 42 (30.4%) 12 (28.6%) 30 (71.4%)  
Absent 96 (69.6%) 18 (18.8%) 78 (81.3%)  












CT IPH    0.597† 
Present 68 (49.3%) 13 (19.1%) 55 (80.9%)  
Absent 70 (50.7%) 17 (24.3%) 53 (75.7%)  
Missing 11 1 10  
CT ICerH    0.524†† 
Present 3 (2.2%) 1 (33.3%) 2 (66.7%)  
Absent 135 (97.8%) 29 (21.5%) 106 (78.5%)  
Missing 11 1 10  
CT DAI    0.364†† 
Present 17 (12.3%) 2 (11.8%) 15 (88.2%)  
Absent 121 (87.7%) 28 (23.1%) 93 (76.9%)  
Missing 11 1 10  
CT Contusion    0.964† 
Present 80 (58.0%) 18 (22.5%) 62 (77.5%)  
Absent 58 (42.0%) 12 (20.7%) 46 (79.3%)  
Missing 11 1 10  
CT ICH    0.999†† 
Present 131 (94.9%) 29 (22.1%) 102 (77.9%)  
Absent 7 (5.1%) 1 (14.3%) 6 (85.7%)  
Missing 11 1 10  
CT extra-axial    0.999†† 
Present 126 (91.3%) 28 (22.2%) 98 (77.8%)  
Absent 12 (8.7%) 2 (16.7%) 10 (83.3%)  
Missing 11 1 10  
CT intra-axial    0.540† 
Present 107 (77.5%) 25 (23.4%) 82 (76.6%)  
Absent 31 (22.5%) 5 (16.1%) 26 (83.9%)  
Missing 11 1 10  
⁎ Mann-Whitney test 
† Chi-square test 




3.2 Bivariate analysis 
The medians of the 1-3 months standardized biomarker levels are presented in Figure 1. There 
were some visible differences in the distribution of the biomarkers between PTD and no PTD 
status, with participants who had PTD having higher values in all biomarkers, except for sIL-6R.  
 
















We summarized all other odds ratios and their 90% confidence intervals in Figure 2. The figure 
shows evidence that there is variation in the effects of the markers on odds of PTD.      
 
Figure 2: Odds ratios with 90% CI from univariate logistic regressions of 12 months PTD with standardized 





Among all the 33 biomarkers considered, 13 (IL-1b, IL-7, IL-10, GM-CSF, TNFα, ITAC, 
Fractalkine, MIP-3a, IL-21, MIP-1a, MIP-1b, sIL-6R, and RANTES) were significant at the 10% 
level. Higher levels of each these inflammatory markers were significantly associated with 
increased odds of PTD, except for sIL-6R, higher levels of which were associated with decreased 
odds of PTD. We presented the statistically significant results in Table 3 (α = 0.10).  
Table 3: Bivariate logistic regression of PTD status with standardized 1-3 months biomarker medians 
Biomarker β OR P-value 
MIP-1a 0.60 1.82 0.006 
RANTES 0.53 1.71 0.012 
ITAC 0.50 1.65 0.016 
MIP-3a 0.62 1.86 0.037 
IL-1b 0.39 1.47 0.046 
TNFα 0.36 1.44 0.054 
sIL-6R -0.45 0.64 0.062 
IL-21 0.35 1.42 0.081 
GM-CSF 0.35 1.41 0.083 
MIP-1b 0.32 1.38 0.087 
IL-7 0.35 1.41 0.088 
IL-10 0.35 1.42 0.091 
Fractalkine 0.36 1.43 0.095 
3.3 Creating inflammatory load score using ridge regression and PCA 
To choose the best value for the tuning parameter of ridge regression, λ, we performed a 5-fold 
cross-validation 1000 times; the resulting distribution of λ is presented in Figure 3a. The mode of 
this empirical distribution was λ = 0.7414409. The inflammatory load score (ILS) was created 




parameter (λ) from the ridge regression are presented in Figure 3b. It shows that the parameter 
estimates become stable very quickly as we increase the values of the penalty parameter λ.  
Figure 3: (a) Distribution of best lambda from repeated CV and (b) plot of coefficient from the ridge 
regression for creating ILS 
 
Table 4 shows the ridge-penalized coefficients for the standardized variables. 



















The PCA-based ILS was created using the first component score, which explained about 45.65% 
variation in the selected biomarkers. The 2nd and 3rd PCs explain 13.90% and 10.56% of the total 
variation. The remaining PCs do not represent the overall inflammatory burden well and would 
not explain much additional variation, hence they were discarded from the analysis. A scree plot 
of the principal components with the bars representing percent variation explained is shown in 
Figure 4. The coefficients of the biomarkers in the linear combinations in PC1, PC2, and PC3 are 
given in Table 5. In the section below, we compare the PCA-based ILS with the ridge regression-
based ILS.  






Table 5: Coefficient of the biomarkers in the first three principal components 
Biomarker PC1 PC2 PC3 
MIP-1a 0.327 0.110 0.072 
RANTES 0.162 0.200 0.522 
ITAC 0.220 0.008 0.534 
MIP-3a 0.305 -0.234 -0.079 
IL-1b 0.320 -0.408 -0.086 
TNFα 0.316 -0.386 -0.052 
sIL-6R -0.030 -0.137 0.542 
IL-21 0.359 0.218 0.040 
GM-CSF 0.245 0.145 -0.308 
MIP-1b 0.297 -0.372 -0.051 
IL-7 0.349 0.148 -0.034 
IL-10 0.259 0.307 -0.062 
Fractalkine 0.237 0.486 -0.155 
 
3.4 Comparison of ridge-based and PCA-based ILS 
We compared the PCA-based ILS with the ridge regression-based ILS in terms their discriminative 
ability of PTD and no PTD cases. We included age, sex, GCS, premorbid depression status, and 
antidepressant use status in the first 6 months as covariates and presented the adjusted odds ratios 
(AORs) from logistic regressions using ridge-based ILS, first PC-based ILS, and first three PC-
based ILS in Tables 6a, 6b and 6c, respectively. The adjusted odds of PTD are estimated to increase 
by 32% (AOR=1.32, p-value=0.002) with each ten-point increase in the ridge-based ILS (i.e., one-







Table 6: Full logistic regression model with ridge-based ILS (n=96) 




(Intercept) 1.56 4.76 1.69 0.356 
Age -0.02 0.98 0.02 0.386 
Sex: Men 0.2 1.22 0.87 0.814 
GCS 0.13 1.14 0.1 0.196 
Premorbid depression: Yes 1.11 3.03 0.79 0.162 
Antidepressant in first 6m: 
Yes -0.56 0.57 0.85 0.509 
ILS (ridge)×10 0.28 1.32 0.09 0.002 
 
The odds of PTD are estimated to increase by 38% (AOR=1.38, p-value=0.002) with each one-
point increase in the first PC-based ILS (Table 7). 
Table 7: Full logistic regression model with PCA-based ILS with the first component (n=96) 




(Intercept) -2.55 0.08 1.19 0.032 
Age -0.02 0.98 0.02 0.396 
Sex: Men -0.03 0.97 0.81 0.97 
GCS 0.13 1.14 0.1 0.203 
Premorbid depression: Yes 1.02 2.77 0.78 0.192 
Antidepressant in first 6m: 
Yes -0.46 0.63 0.83 0.579 
ILS (PC1) 0.32 1.38 0.1 0.002 
The odds of PTD are estimated to increase by 43% (AOR=1.43, p-value=0.002) with each one-
point increase in the first PC-based ILS (Table 8). The 2nd and 3rd PC-based ILS were not 
significantly associated with PTD.  
Table 8: Full logistic regression model with PCA-based ILS with the first three components (n=96) 




(Intercept) -2.56 0.08 1.22 0.035 
Age -0.02 0.98 0.02 0.411 
Sex: Men 0.06 1.06 0.87 0.944 





Yes 1.1 3 0.79 0.163 
Antidepressant in first 6m: 
Yes -0.56 0.57 0.83 0.503 
ILS (PC1) 0.36 1.43 0.12 0.002 
ILS (PC2) 0.24 1.27 0.2 0.246 
ILS (PC3) 0.07 1.07 0.26 0.796 
The distribution of ridge-based and 1st PC-based ILS values between PTD and no PTD categories 
are presented in Figure 5. The distributional difference between the PTD and no PTD categories 
look very similar in shape for both ILS. Note that the ranges of X-axis (i.e., ILS values) are 
different because of the arbitrariness of the different methods being used to create them. To aid 
the interpretation, the ILS variables were transformed into percentile ranks. A one percentile 
change in the ridge-based ILS was associated with 4.40% higher odds of PTD (OR=1.04, p-
value=0.003) while a one percentile change in the first PC-based ILS was associated with 4.35% 
higher odds of PTD (OR=1.04, p-value=0.003). Hence, there was very little difference between 
the two ILS.     





We calculated the predicted probabilities of PTD from the models with PCA-based ILS, ridge-
based ILS, and without ILS and compared the area under the receiver operating characteristics 
curves in Figure 6. The model without any ILS had an AUC of 64.5%, whereas the ROC for the 
model with 1st PC-based ILS was 81.6%. The model with ridge-based ILS outperformed the first 
three PC-based ILS (AUC=83.6%) only marginally and had an AUC of 84.1%. The DeLong's test 
for two correlated ROC curves did not show any statistically significant difference between the 
two curves (Z = 1.60, p-value = 0.110).  
 





3.5 Prediction performance of logistic regression and random forest model 
The results of the prediction performance of logistic regression and random forest model on the 
test data are presented in Table 9. The sensitivity was set to 80% using the training data to find the 
probability threshold for classification. The test set consisted of 28 observations with 4 PTD cases. 
The overall accuracy of the logistic regression model was 85.71% with a sensitivity of 75% and a 
specificity of 87.5%. The positive predictive value was only 50%. The prevalence of PTD was 
about 14% in the sample, but the detection prevalence was 21.43%. The Yuden’s index was 62.5% 
which meant the model was useful in predicting PTD to some extent. The random forest model 
failed to detect any of the 4 PTD cases in the test data. Hence, the other metrics were not reported.  
Table 9: Accuracy measures on the test data using a 70-30 split with sensitivity set at 80% for training data 







Sensitivity 0.7500 0 
Specificity 0.8750 1 
Positive predictive value 0.5000 - 
Negative predictive value 0.9545 - 
Detection rate 0.1071 - 
Detection prevalence 0.2143 - 
Balanced accuracy 0.8125 - 
Yuden’s index 0.6250 - 
 
The reason for the poor performance of the random forest model was the small size of the 
test set and the high class-imbalance. Therefore, we up-sampled PTD cases in the test data to 
evaluate the models (Table 10). With up-sampling the random forest model had higher accuracy 




50% for the random forest model while it was 75% for the logistic regression model. However, 
there were only 4 PTD cases in the test data and the sensitivity metric can be arbitrary. The 
Yuden’s indexes do not suggest that either of these models was very useful in predicting PTD, 
with values close to 50%.    
Table 10: Accuracy measures on the test data using a 70-30 split and up-sampling of PTD cases 







Sensitivity 0.7500 0.50000 
Specificity 0.7917 0.95833 
Positive predictive value 0.3750 0.66667 
Negative predictive value 0.9500 0.92000 
Detection rate 0.1071 0.07143 
Detection prevalence 0.2857 0.10714 
Balanced accuracy 0.7708 0.72917 
Yuden’s index 0.5417 0.45833 
 
The sample size was small enough to not provide us with a moderately sized test set. 
Moreover, there was high class-imbalance present in our sample. Hence, we performed a ‘strong 
internal validation’. The process involved taking B=100 bootstrap samples and using them each 
time to train the model and using the original sample as the test set. The averages of the prediction 
performance metrics were reported in Table 11 for classifications with thresholds chosen by setting 
sensitivity at 80% using the training data. The detection prevalence was very high (30.85%) for 
the logistic regression model while it was quite conservative for the random forest model (7.31%). 
As a result, the sensitivity of the random forest model was also poor (48.21%). The specificity of 
the random forest model was, however, almost perfect (99.67%). The positive predictive value of 




model (35.10%). Overall, the Yuden’s indexes were not convincing as a measure of overall 
predictive performance for either of these models (expected to be > 0.5). 
Table 11: Strong internal validation by bootstrapping with sensitivity set at 80% for training data 







Sensitivity 0.6807 0.4821 
Specificity 0.755 0.9967 
Positive predictive value 0.351 0.9669 
Negative predictive value 0.9346 0.9187 
Detection rate 0.0993 0.0703 
Detection prevalence 0.3085 0.0731 
Balanced accuracy 0.7179 0.7394 
Yuden’s index 0.4357 0.4789 
 
Lastly, we performed the strong internal validation using the up-sampling technique with 
both logistic regression and random forest (Table 12). The random forest model with up-sampling 
outperformed all other models in almost all metrics. The accuracy was 92.4%, with a sensitivity 
of 69.9% and a specificity of 96.2%. The performance of the logistic regression model was also 
improved (accuracy: 77.81%, sensitivity: 63.93%, specificity: 80.18%). However, it suffered from 
poor positive predictive value (36.17%). The detection prevalence was still high (26.25%). The 
detection prevalence of the random forest model (13.4%) was almost close to the PTD prevalence 
in the sample. The Yuden’s index was 66.1% for the random forest model with up-sampling, which 






Table 12: Strong internal validation by bootstrapping with up-sampling of PTD cases 







Sensitivity 0.6393 0.699 
Specificity 0.8018 0.962 
Positive predictive value 0.3617 0.778 
Negative predictive value 0.9294 0.95 
Detection rate 0.0932 0.102 
Detection prevalence 0.2625 0.134 
Balanced accuracy 0.7206 0.831 






Diagnostic and Prediction Performance of the Models 
We used ridge regression and PCA to obtain patient-specific ILS, which are novel 
approaches in the TBI space. The diagnostic performance of ILS created using ridge regression 
and PCA was tested using the whole cohort. The model with ridge-based ILS marginally succeeded 
to surpass the PCA derived model using a three PC-based ILS. We believe both methods can be 
useful in creating an ILS and are comparable in terms of their diagnostic performance based on 
AUC. We then proceeded with the ridge-based ILS to compare the predictive performance of 
logistic regression and random forest with our data. The predictive accuracy metrics were better 
for the random forest model when using an up-sampling technique and when tested using a robust 
internal validation methodology. The independent test set with a 70-30 split was very small to 
assess which model performed better. When using our robust internal validation methodology, the 
logistic regression continued to have a relatively poor positive predictive value. However, the 
sensitivity and specificity were moderate while using the threshold set by fixing training set 
sensitivity at 80%. The advantage of using a logistic regression for classification is its ease of use 
for clinicians. Thresholds can be defined, possibly by averaging over the ones identified with the 
bootstrapping and can be readily used. The best performing model, the random forest model with 
up-sampling technique, requires setting up an app or a calculation system that can classify a new 
patient into PTD or no PTD categories. Logistic regression was also more open to classifying cases 




and without up-sampling) achieved very high specificity. However, in our case, early detection of 
a person with PTD is more important than correctly detecting a patient with no PTD. Hence, 
sensitivity holds significant weight when choosing between model complexity and convenience.  
 
Inflammatory Hypothesis of Depression & Sickness Syndrome 
Looking at cytokine or inflammatory load has potential relevance in the context of 
antidepressant treatment (Köhler et al., 2018). What has been deemed the “inflammatory 
hypothesis of depression” suggests a dynamic interplay between domains of the immune system, 
neurotransmitters, and neuro-circuitry influence behavioral changes, including the onset of 
depressive symptoms (Michael Maes, 1995; Miller & Raison, 2015). The development of 
depression is thought to be relevant to a pathogen host defense process. That is, an inflammatory 
response is mounted in response to environmental or pathogenic exposure or stressor.  
Typically, a pro-inflammatory, anti-pathogenic response is intended to eliminate pathogen 
exposure (Raison & Miller, 2013). Exposure to pro-inflammatory cytokines, particularly 
chronically, can result in moods and behaviors related to “sickness syndrome” which overlap with 
depression symptoms (Raison et al., 2010; Slavich & Irwin, 2014). These symptoms include lack 
of energy and interest, decreased appetite, and fatigue, all of which are common in depression 
(Anisman et al., 2005; R. Dantzer, 2008; Robert Dantzer, 2006; Michael Maes et al., 2011; Myers, 
2008; Reichenberg et al., 2001). While sickness behavior is adaptive and helps the body respond 
to acute injury or infection, it becomes maladaptive if it persists beyond 3-6 weeks after injury 
(Robert Dantzer, 2006; Michael Maes et al., 2011). This marks a transition from acute, adaptive 




Other diseases with a prominent systemic pro-inflammatory state have also been associated 
with increased depression risk (Raison et al., 2010). For example, systemic and neuroinflammation 
have an impact on classic disease models such as multiple sclerosis (Christensen et al., 2013; 
Jadidi-Niaragh & Mirshafiey, 2011). Autoimmune diseases, including multiple sclerosis, have 
high depression rates wherein systemic inflammation is considered to be a central disease 
mechanism (Morris et al., 2015; Pryce & Fontana, 2016). Inflammatory mechanistic frameworks 
that drive depression also impact specific symptoms associated with depression such as fatigue 
and sleep dysregulation (Alekseeva et al., 2019). Following TBI, which induces a pro-
inflammatory response to circulating brain-derived antigen, this susceptibly to depression is likely 
exacerbated. Systemic inflammatory signaling is also known to activate the HPA and the 
sympathetic nervous system (Elenkov, 2008; Elenkov et al., 2005), both of which are also 
persistently activated in the setting of major trauma, including TBI (Wagner Humoral triad) and 
impact neurotrophin signaling, which is also implicated with PTD (Failla et al., 2016) as well as 
MDD (Hing et al., 2018; Kraus et al., 2019; Mondal & Fatima, 2019). To our knowledge this is 
the first TBI study published directly implicating chronic inflammatory burden with PTD.  To that 
end we have rigorously applied quantitative methods to identify inflammatory markers associated 
with PTD in our population as well as generate and validate a weighted ILS, based on 
inflammatory levels over the first three months post-injury that has significant predictive capacity.  
Markers used for ILS formulation implicate multiple arms of the immune system as increasing 
PTD risk at 12 months post injury.  Below we outline the unique immune domain-specific profiles 





Innate Immunity & Chemokines 
The most relevant PTD markers in the ILS formation were among the innate, 
proinflammatory molecules (IL-1β, MIP-3a, MIP-1a) and chemo-attractant molecules (ITAC and 
RANTES). Additionally, GM-CSF, TNFα, and MIP-1b were associated with depression status 
albeit to a lesser degree. Historically, depressed patients, even in the absence of trauma, express 
increased serum pro-inflammatory biomarkers including IL-1β, IL-6, TNFα, and IFNγ and 
likewise, show compensatory increases in anti-inflammatory molecules IL-4 and IL-10 (R. 
Dantzer, 2008; Littrell, 2012; Michael Maes, 2011). Neurotransmitter depletion including 
serotonin, norepinephrine, and dopamine have all been implicated in the “monoamine hypothesis” 
of imbalanced brain chemistry related to depression (Bruno et al., 2020; Perez-Caballero et al., 
2019; Spellman & Liston, 2020). After TBI, the hypothalamic pituitary adrenal (HPA)-axis 
exhibits a stress-like response to the neurologic insult that fails to normalize (Ranganathan et al., 
2016; Martina Santarsieri et al., 2014; Amy K. Wagner et al., 2011) and a proinflammatory 
environment (M. Santarsieri et al., 2015; Schuster et al., 2017) similar to that observed with other 
disease associated sickness behavior inflammatory profiles and contributes to depressive 
symptoms post-TBI. These innate proinflammatory molecules also activate the HPA axis, and, in 
turn, affect serotonin precursor levels (Dunn et al., 1999), and serotonin signaling is widely 
implicated in depression (Krishnan & Nestler, 2008; M. Maes et al., 2011).  
Likewise, chemokines are key in orchestrating the recruitment and activation of effector 
molecules to the sites of injury; however, they have also been implicated in HPA-axis and 
neuroendocrine dysregulation (Callewaere et al., 2007). With persistent chemo-attractant 




HPA-axis dysfunction may increase depression pathophysiology (Pariante & Lightman, 2008). 
The neuroendocrine dysfunction that accompanies depression, particularly after trauma, is a 
compelling area for further exploration. 
 
Adaptive Immunity 
Adaptive immunity related markers including IL-7, IL-21 and Fractalkine were implicated 
in depression at the p<0.1 threshold. While the cell-mediated innate immune relationship to 
depression was more dominant, there is still compelling evidence for humoral signaling and the 
immune response following TBI due to the interrelationships between innate and adaptive immune 
systems. In particular, T cell subsets may be imbalanced due to the dysregulated cytokine signaling 
in favor of a pathogenic Th1 phenotype and a down-regulation of Treg cells which would typically 
reduce chronic inflammation (Miller, 2010). In particular, IL-7 has been implicated in generating 
a sustained and effective immune response after TBI (Katzman et al., 2011). From a chronic TBI 
perspective, elevated IL-7 may have some maladaptive functions, as it is linked to numerous 
autoimmune disorders; further, an autoimmune response has recently been demonstrated after TBI 
(Zhang et al., 2014). Immunological memory associated with adaptive immunity may relate the 
experience of stress exposure (or elevated inflammatory profile) with the onset of depressive and 
mood disorders (Miller, 2010).  
 
Soluble Molecules 
sIL-6R was the only resulting molecule reduced in PTD cases. Membrane-bound IL-6R is 




immune activation deemed “classical activation” (Baran et al., 2018; Rose-John, 2006). Upon 
activation, IL-6R is shed via proteolytic cleavage and released into circulation. The circulating 
sIL-6R has affinity for IL-6 and, when bound, the IL-6/sIL-6R complex acts via “trans-signaling” 
communicating pro-inflammatory signals far from the site of initial injury when bound to the 
ubiquitously expressed membrane-bound gp130 (Garbers et al., 2011). Noting the multifaceted 
nature of IL-6 and its spectrum of roles with respect to its receptors, the inverse finding between 
sIL-6R and PTD presence in this instance is complex. In that case, sIL-6R in isolation would be 
reduced when trans-signaling mechanisms are dominant and driving pathologic effects of IL-6 
(Campbell et al., 2014).  The depletion of serum sIL-6R in PTD may also be a result of increased 
blood brain barrier (BBB) crossing and increased IL-6 trans-signaling in the brain, further 
perpetuating neurological behavioral deficits (Patel et al., 2012). This relationship should be 
further explored by utilizing IL-6 family marker ratios to determine the balance of signaling 
mechanisms occurring. 
 
Limitations and Future Directions 
While the findings here are compelling there are some study limitations to consider.  One 
limitation is the relatively low sample size for this study and the need for further validation of the 
ILS in an independent population. Larger study numbers may also allow for assessing if/how 
inflammatory load interacts with medication use to impact anti-depressant effectiveness. Also, 
there were no direct measurements of CNS inflammation. However future work should follow 
previously published methodologies (Mondello et al., 2020; Osier et al., 2018) to include blood 




There may also be additional inflammatory markers not measured here that may inform PTD risk. 
Exploring inflammatory marker associations with other secondary conditions such as post-
traumatic epilepsy, headache, neuroendocrine dysfunction, cognition, and behavior may identify 
common inflammatory patterns associated with pathology and poor outcome. The inflammatory 
differences by PTD status suggest common immune-related pathophysiology underlying 
depression and other survivor-based outcomes after TBI from other of our work, such as 
headaches, cognition, and even functional deficits (DRS score) and global recovery (GOS score).  
The ILS formulated here may have utility as a screening tool, that when paired with a 
clinical decision algorithm, as an effective early identifier of those at risk for PTD and potential 
responder to anti-inflammatory strategies and immunotherapy approaches that can be paired with 
other non-pharmacological strategies to curb depressive symptoms (e.g. exercise, cognitive 
behavioral therapy). Targeted immunotherapy approaches for likely responders may curb 
pathophysiological mechanisms after TBI that exacerbate PTD.  
Some preliminary evidence suggests antidepressant medication and cognitive behavioral 
therapy may be efficacious for treating PTD (Fann, Hart, et al., 2009; Soo & Tate, 1996), however, 
previous systematic reviews have revealed that there are currently no psychotherapeutic or 
rehabilitation interventions that prospectively target depression or anxiety disorders after TBI 
(Hart et al., 2012; Ownsworth & Oei, 1998) Based on our findings, we hypothesize that the relative 
ineffectiveness of antidepressants, including selective serotonin re-uptake inhibitors (SSRIs), in 
the setting of TBI may, in part, be due to the inflammatory burden observed in the context of PTD.  
In fact, some studies support this hypothesis by showing increased SSRI efficacy with elevated 




formulation informs likely respondership to SSRI treatment, both with/without co-treatment with 
an anti-inflammatory and/or immunotherapy strategy. Our previous work suggesting increased 
depression risk due to genetic variation in the SLC6A4 gene (Failla et al., 2013) also provides an 
opportunity for future work to consider if/how serotonin system genetics might interact with 
inflammatory pathways to impact both PTD risk and treatment response. 
The random forest model with up-sampling technique was the best performer in our 
internal validation process. But this model is not readily usable by someone who do not have the 
expertise to code for this model. To make it usable by the clinicians, we plan to build an R Shiny 
app in the future that can be used to assess new patient data without the need to know the coding. 
This will also help us understand better the effects and utility of ILS on model prediction.  
Conclusions 
These findings support a systemic inflammatory hypothesis for PTD. It is probable that 
inflammation is a common link between personal biology and recovery course that underlies 
multidimensional outcomes post-TBI. This study demonstrates great promise for early detection 
and/or risk stratification of PTD which can help clinicians explore the treatment options for 
depression before it becomes severe. Efforts in improving the prediction accuracy, especially the 
sensitivity, can be continued using other machine learning techniques. This study may also 
encourage research funding for obtaining a larger sample size, so that the relationships among the 
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